Thera-SAbDab

PIDILIZUMAB

>   Structural Summary
TherapeuticPidilizumab
TargetPDCD1
Heavy ChainQVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS
Light ChainEIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedAmerican Cancer Society, Beth Israel Deaconess Medical Center, CureTech, Georgia Regents University, Hadassah Medical Organization, Northwestern University, The Ohio State University Comprehensive Cancer Center, University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia, Colorectal cancer, Diffuse large B cell lymphoma, Follicular lymphoma, Malignant melanoma, Multiple myeloma, Pancreatic cancer, Prostate cancer, Renal cell carcinoma, Glioma, Hepatitis C, Liver cancer
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]